Related Experiment Video

Updated: May 15, 2026

Isolation of Neonatal Extrahepatic Cholangiocytes
07:54

Isolation of Neonatal Extrahepatic Cholangiocytes

Published on: June 5, 2014

Hepatitis in an infant treated with octreotide for congenital hyperinsulinism

Ilana Koren1, Arieh Riskin, Winfried Barthlen

  • 1Armon Child Center, Haifa, Israel. ilanaza2@clalit.org.il

Journal of Pediatric Endocrinology & Metabolism : JPEM
|January 19, 2013
PubMed

Insights

Octreotide treatment for congenital hyperinsulinism can cause liver injury. This infant experienced hepatitis, which resolved after stopping octreotide, highlighting the need for liver function monitoring.

Area of Science:

  • Pediatric Endocrinology
  • Hepatology
  • Clinical Pharmacology

Background:

  • Congenital hyperinsulinism (CHI) involves hypoglycemia due to genetic defects in insulin secretion.
  • Octreotide, a somatostatin analogue, is a key pharmaceutical for managing CHI.
  • Drug-induced liver injury is a significant concern in pediatric pharmacotherapy.

More Related Videos

Intrasplenic Transplantation of Hepatocytes After Partial Hepatectomy in NOD.SCID Mice11:24

Intrasplenic Transplantation of Hepatocytes After Partial Hepatectomy in NOD.SCID Mice

Published on: February 10, 2018

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...